Scope and patent-landscape analysis for US Patent 9,968,659 (liraglutide MACE reduction in type 2 diabetes with cardiovascular disease)
US 9,968,659 is a U.S. method-of-treatment patent that claims reducing major adverse cardiovascular events (MACE) in patients with type 2 diabetes (T2D) and established cardiovascular disease (CVD) using liraglutide while excluding use of a dipeptidyl peptidase-4 (DPP-4) inhibitor. The independent claim set is method-centric (administration), with dependent claims narrowing to concomitant cardiovascular medication, age, liraglutide dose levels (0.6/1.2/1.8 mg), and detailed formulation/concentration and excipient ranges for a liraglutide composition.
Key commercial hook: the patent targets the specific clinical positioning of liraglutide for cardiovascular risk reduction, with a patient-comorbidity constraint (no DPP-4 inhibitor) and multiple “claim ladders” that can be asserted against (i) generic and branded liraglutide prescribers and (ii) specific formulation and concentration presentations, depending on how infringement is litigated.
Key enforcement reality check: because the claims are administration methods, direct infringement typically hinges on proving that the accused party (often the marketer/distributor) induced performance by prescribing and administering the claimed regimen, or that a licensed provider performed the steps. The patent’s formulation claims also create a second, more product-centric infringement pathway if a litigant’s formulation matches the claimed “consists essentially of/comprises” language and excipient ranges or exact exemplified composition.
What claims are in US Patent 9,968,659 and what is the protected invention?
Short answer (scope): The patent protects methods for reducing MACE (cardiovascular death, non-fatal MI, non-fatal stroke) in T2D patients with CVD using liraglutide, excluding patients on DPP-4 inhibitors, and includes dependent claims that lock in specific liraglutide doses and composition ranges for a specific injectable formulation.
Independent claim themes
Claim 1 (administration method with eligibility constraint)
- Patient: T2D and CVD.
- Intervention: administering liraglutide in a therapeutically effective amount.
- Exclusion: subject is not administered a DPP-4 inhibitor.
- Outcome: MACE selected from cardiovascular death, non-fatal MI, non-fatal stroke.
Claim 6 (administration method with composition “consists essentially of”)
- Similar patient and outcome.
- Product constraint: pharmaceutical composition consists essentially of liraglutide (therapeutically effective amount) and excipients.
Claim 13 (administration method with composition “comprises” and only active ingredient)
- Product constraint: composition comprises liraglutide as the only active therapeutic ingredient.
- Outcome and patient population same as above.
Dependent claim narrowing and what each does
- Claim 2: administration to subjects also receiving cardiovascular medications.
- Claim 3 / Claim 5 / Claim 7 / Claim 9 / Claim 14 / Claim 16: subjects aged ≥50 years.
- Claim 4 / Claim 8 / Claim 15: liraglutide dose levels limited to 0.6 mg, 1.2 mg, 1.8 mg.
- Claim 10: excipient category examples: buffer system, preservative, tonicity agent, chelating agent, stabilizer, surfactant.
- Claims 11-12: tight formulation ranges and a specific example:
- 6 mg/mL liraglutide
- 2–15 mM phosphate buffer
- 2–25 mg/mL propylene glycol
- 1–18 mg/mL phenol
- pH 7.5–9.0
- Example in Claim 12: 6 mg/mL, 1.42 mg/mL disodium phosphate dihydrate, 14.0 mg/mL propylene glycol, 5.5 mg/mL phenol, pH 8.15
- Claims 17-18: similar “concentration + excipient + pH” limitations tied to the “only active ingredient” claim pathway.
Practical claim construction levers (based on claim language)
- Eligibility constraint (“not administered a DPP-4 inhibitor”) is a key differentiator. It can be used to separate an accused regimen from a broader T2D standard-of-care where DPP-4 inhibitors may be used.
- Dose lock-in (0.6/1.2/1.8 mg) narrows to specific titration/maintenance dosing commonly associated with liraglutide use in practice.
- Composition constraints:
- “consists essentially of” (Claim 6) is a middle ground: it permits excipients but limits additional active ingredients or components that would materially affect properties.
- “as the only active therapeutic ingredient” (Claim 13) is stricter on actives.
- “comprises” (Claim 13) still allows additional non-active excipients, but the dependent claims 17-18 and 10 narrow excipient sets and ranges.
What patient population and clinical endpoint are required to infringe?
Claimed patient: a subject with type 2 diabetes and cardiovascular disease.
Claimed endpoints: MACE is limited to:
- cardiovascular death,
- non-fatal myocardial infarction,
- non-fatal stroke.
DPP-4 inhibitor exclusion: the subject is not administered a DPP-4 inhibitor.
How strict is the DPP-4 inhibitor “not administered” limitation?
Because the claim language requires the subject is “not administered a DPP-4 inhibitor,” infringement turns on whether the accused treatment regimen includes a DPP-4 inhibitor. That may drive:
- whether a prescriber combined liraglutide with a DPP-4 inhibitor (reducing infringement risk for that specific case), versus
- whether the claimed patient subgroup was maintained without DPP-4 inhibitor therapy during the relevant period.
This limitation is often the most litigated because it is patient-specific and may require medical record evidence (medication lists, claims, and clinical notes).
How is MACE defined operationally?
The patent does not re-define MACE beyond the three components. In enforcement, that means plaintiffs typically map trial endpoints (or real-world outcomes) to these categories.
What dosing and age limitations are embedded in US 9,968,659?
Liraglutide dose levels
Dependent claims restrict liraglutide to 0.6 mg, 1.2 mg, and 1.8 mg. This narrows the administration step.
Age
Dependent claims require subject age ≥50 in multiple claim paths.
Enforcement impact
- If an accused use involves younger patients or titration beyond these listed dose points, those dependent claims may be harder to assert.
- The independent claim(s) still require “therapeutically effective amount” without dose-specific limitation, but dependent claim coverage may be materially relevant to case strategy.
What formulation and excipient ranges are claimed, and how do “consists essentially of” vs “only active ingredient” matter?
Formulation-scoped dependent claims
The most concrete product coverage is in Claims 11-12 (on the Claim 6 branch) and Claims 17-18 (on the Claim 13 branch). They include:
Core composition (range-limited):
- liraglutide: about 6 mg/mL
- phosphate buffer: about 2–15 mM
- propylene glycol: about 2–25 mg/mL
- phenol: about 1–18 mg/mL
- pH: 7.5–9.0
Example composition (tight lock-in):
- liraglutide: 6 mg/mL
- disodium phosphate dihydrate: 1.42 mg/mL
- propylene glycol: 14.0 mg/mL
- phenol: 5.5 mg/mL
- pH: 8.15
“Consists essentially of” (Claim 6)
This phrase generally means:
- the composition is liraglutide plus excipients,
- additional components are allowed only if they do not materially change the basic and novel characteristics.
For litigation, defendants often argue that their formulation has additional ingredients or different excipient systems that materially affect stability, tonicity, pH buffering capacity, preservative system behavior, or other critical properties.
“Only active therapeutic ingredient” (Claim 13)
This is narrower than “consists essentially of” regarding actives. It still allows other non-active excipients, but it blocks additional active therapeutic ingredients.
Infringement pathway split
- If a generic/biosimilar-type entrant used different actives, Claim 13 would likely not read.
- If an entrant uses only liraglutide as the active (as with generic liraglutide products), the “only active” limitation is easier for plaintiffs to satisfy, shifting the fight to excipient system and concentration/pH ranges.
What is the likely patent landscape risk for generics and new liraglutide formulations?
Because your prompt includes only the asserted claims text and does not provide the patent’s bibliographic details (filing date, priority, expiration, related continuations, or prosecution history), a complete, verified landscape across all U.S. related patents cannot be produced from the provided information alone.
What can be concluded from the claim set itself:
- There are at least two distinct infringement theories:
- Method-of-use: reduction of MACE in T2D/CVD patients with no DPP-4 inhibitor, via liraglutide administration.
- Composition/formulation: specific injectable composition constraints (concentration/excipient ranges and pH; plus “only active ingredient” framing).
- The patent is positioned to create launch friction for:
- entrants who sell liraglutide formulations that match the excipient concentration and pH ranges (especially if they are “designed to” and labeled for cardiovascular risk reduction contexts), and
- prescribers/marketers whose label or supported use aligns with MACE reduction in this subgroup and avoids DPP-4 inhibitor combination.
Actionable risk mapping for a would-be challenger (based purely on claim language)
- If a generic marketer wants to reduce risk:
- consider ensuring labeling and promotional support do not encourage the claimed clinical method for MACE reduction in the specified subgroup, and
- avoid (as a practical matter) any positioning that relies on patient selection “not administered a DPP-4 inhibitor.”
- If an entrant’s formulation differs in pH or excipient concentrations outside the claimed ranges (or uses a materially different buffering or preservative system not captured by the described ranges), it may avoid dependent formulation claims even if independent method claims remain.
How strong are US 9,968,659 claims as enforcement tools?
Strengths (from claim structure)
- Clear clinical outcome definition (MACE components).
- Strong patient-selection feature (T2D + CVD).
- Distinct exclusion feature (no DPP-4 inhibitor).
- Multiple dependent ladders: age and dose, plus a detailed formulation example and ranges.
Potential vulnerabilities (from claim structure)
- “not administered a DPP-4 inhibitor” is patient-record dependent and can create evidentiary defenses.
- Formulation dependent claims are range-bound and depend on exact or near-exact pH and excipient concentrations.
- If a product label and real-world use focus on different populations (for example, without “cardiovascular disease” requirement) or different endpoints, infringement may narrow.
Key takeaways
- US 9,968,659 protects liraglutide-administered methods to reduce MACE (cardiovascular death, non-fatal MI, non-fatal stroke) in T2D patients with CVD.
- The DPP-4 inhibitor exclusion is a central differentiator in Claim 1 and likely drives subgroup-specific infringement.
- The patent provides two enforcement pathways: method-of-use and formulation-specific composition constraints (including a detailed exemplar at 6 mg/mL, pH 8.15, with specified phosphate buffer, propylene glycol, and phenol).
- Dependent claims add practical narrowing via age ≥50, and liraglutide doses 0.6/1.2/1.8 mg, plus constraints on excipients.
- For a generic or formulation entrant, the main infringement questions become: (i) does the use match the “no DPP-4 inhibitor” subgroup and MACE outcome, and (ii) does the marketed/used formulation match the claimed concentration, excipient ranges, and pH.
FAQs
-
What does “subject is not administered a dipeptidyl peptidase-4 inhibitor” mean for real-world infringement analysis?
It requires patient-specific evidence that the regimen excluded DPP-4 inhibitors during the relevant treatment window.
-
Does “consists essentially of liraglutide and excipients” allow additional inactive components outside the claimed excipient categories?
It allows non-excipient components only if they do not materially affect the basic and novel characteristics, but dependent claims narrow the excipient set and ranges.
-
If a product uses the same liraglutide concentration but a different pH or buffer system, which dependent claims are most at risk?
The dependent formulation claims (11-12 and 17-18) are most sensitive because they specify pH ranges and exact exemplified values.
-
Can the patent be asserted against off-label use for MACE reduction in T2D/CVD patients?
The claim language requires the method steps; whether it is practically asserted depends on proof of administration and inducement.
-
How do the dose-limited dependent claims affect strategy compared with the therapeutically effective amount independent coverage?
Dependent dose claims tighten coverage to 0.6/1.2/1.8 mg, while the independent claims can still be asserted under “therapeutically effective amount” if dosing falls within that concept under the evidence.
References (APA)
- United States Patent 9,968,659.
